Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01316432
Other study ID # NIL-CDNP-CT006
Secondary ID
Status Completed
Phase Phase 1
First received March 14, 2011
Last updated October 16, 2012
Start date May 2011
Est. completion date November 2011

Study information

Verified date October 2012
Source Nile Therapeutics
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purposed of the study is to evaluate the pharmacokinetics (PK) response of continuous subcutaneous (SQ) infusion of cenderitide, as compared with a single SQ bolus.


Recruitment information / eligibility

Status Completed
Enrollment 58
Est. completion date November 2011
Est. primary completion date October 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male or female = 18 years of age.

- Documented systolic heart failure with ejection fraction (EF) = 40%

- Clinical evidence of volume overload

- Systolic blood pressure = 120 mmHg and = 200 mmHg and diastolic blood pressure > 60 mmHg and < 110 mmHg at the time of screening.

- Stable doses of oral medication at least 24 hours prior to screening

- No known allergy or contraindication to furosemide (Lasix®)

- Female patients must be post-menopausal or surgically sterile. A woman may be considered to be surgically sterilized if she has had a bilateral tubal ligation (for at least 6 months), bilateral oophorectomy or complete hysterectomy.

- Be adequately informed of the nature and risks of the study and give written informed consent prior to receiving study medication.

Exclusion Criteria:

- Acute or suspected acute myocardial infarction (AMI) or troponin levels > 5X the upper limit of normal at the institution's local laboratory and accompanied by dynamic ECG changes consistent with AMI

- Clinical diagnosis of acute coronary syndrome (ACS) within 30 days prior to screening.

- Evidence of uncorrected volume or sodium depletion (NA = 130) or other condition that would predispose the patient to adverse events.

- Clinically significant aortic or mitral valve stenosis.

- Temperature > 38°C (oral or equivalent), sepsis or active infection requiring IV anti-microbial treatment.

- ADHF associated with significant arrhythmias (ventricular tachycardia, bradyarrhythmias with ventricular rate < 45 beats per minute or atrial fibrillation/flutter with ventricular response of > 160 beats per minute).

- Severe renal failure defined as creatinine clearance < 30 mL/min as estimated by both the Cockcroft-Gault and the Modification of Diet in Renal Disease (MDRD) equations.

- Significant pulmonary disease (history of oral daily steroid dependency, history of CO2 retention or need for intubation for acute exacerbation, or currently receiving IV steroids).

- Any organ transplant recipient, currently listed (anticipated in the next 60 days) for transplant, or admitted for cardiac transplantation.

- Major surgery within 30 days.

- Major neurologic event, including cerebrovascular events in the prior 60 days.

- Acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy (not including restrictive mitral filling patterns).

- Known hepatic impairment

- Received an investigational drug within 30 days prior to screening.

- Women who are pregnant or breastfeeding.

- Known hypersensitivity or allergy to natriuretic peptide or its components, nesiritide, other natriuretic peptides or related compounds.

- Any condition which, in the opinion of the Investigator, could interfere with, or for which the treatment might interfere with the conduct of the study, or which would unacceptably increase the risk of the patient's participation in the study.

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)


Related Conditions & MeSH terms


Intervention

Drug:
Cenderitide
Cenderitide is a novel rationally designed chimeric natriuretic peptide to be administered in this trial as either a subcutaneous injection or infusion.
Other:
Placebo
Placebo will be administered as a 24-hour SQ infusion

Locations

Country Name City State
United States Jacksonville Center for Clinical Research Jacksonville Florida
United States Analab Clinical Research, Inc. Lenexa Kansas
United States Benchmark Research Metairie Louisiana
United States Hennepin County Medical Center Minneapolis Minnesota
United States Orange County Research Center Tustin California

Sponsors (2)

Lead Sponsor Collaborator
Nile Therapeutics Integrium

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pharmacokinetics (PK) Pharmacokinetic measurements of subcutaneous cenderitide infusion compared with a subcutaneous bolus administration Up to 36 hours No
Secondary Pharmacodynamics (PD) Pharmacodynamics, safey and tolerability will be measured by BP, heart rate, and plasma cGMP after administration. Up to 36 hours No
See also
  Status Clinical Trial Phase
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy